Oral Immunotherapy With Partially Hydrolyzed Wheat-Based Cereals: A Pilot Study
| Autor: | Massimo Fontanesi, Jacqueline Wassenberg, Sandra Denery-Papini, Sophie Nutten, Philippe Eigenmann, Adrian Zuercher, Sophie Pecquet, Annick Mercenier, Andreas Jung, Antoine Wermeille, Yvonne M. Vissers, Sigrid Sjölander, Roger Lauener, Rodolphe Fritsché |
|---|---|
| Přispěvatelé: | University of Zurich, Christine Kühne Center, Partenaires INRAE, Children's Hospital of Eastern Switzerland St.Gallen, Hôpitaux Universitaires de Genève (HUG), Centre Hospitalier Universitaire Vaudois (CHUV), University Children’s Hospital Zurich, Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA), Institut National de la Recherche Agronomique (INRA), Thermo Fisher Scientific Inc., Nestlé, CSL Behring AG, Nestec Ltd, Vevey, Switzerland, Nutten, Sophie |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Allergy Oral immunotherapy medicine.medical_treatment education hydrolysate Pharmacy 610 Medicine & health behavioral disciplines and activities 03 medical and health sciences 0302 clinical medicine Internal medicine wheat [SDV.IDA]Life Sciences [q-bio]/Food engineering Clinical endpoint Medicine [SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering Adverse effect Original Research 2. Zero hunger 030109 nutrition & dietetics ddc:618 business.industry General Engineering lcsh:RJ1-570 oral immunotherapy food and beverages lcsh:Pediatrics Immunotherapy medicine.disease allergy 3. Good health 030228 respiratory system 10036 Medical Clinic Maximum dose business Wheat allergy Biomedical engineering |
| Zdroj: | Clinical medicine insights. Pediatrics, vol. 11, pp. 1179556517730018 Clinical Medicine Insights. Pediatrics Clinical Medicine Insights: Pediatrics, Vol. 11 (2017) P. 1179556517730018 Clinical Medicine Insights. Pediatrics, 2017, 11, pp.1-6. ⟨10.1177/1179556517730018⟩ Clinical Medicine Insights. Pediatrics (11), 1-6. (2017) Clinical Medicine Insights: Pediatrics, Vol 11 (2017) |
| ISSN: | 1179-5565 |
| Popis: | International audience; To date, only few studies have assessed oral immunotherapy (OIT) for wheat allergy and often describe severe adverse reactions during therapy. We developed partially hydrolyzed wheat-based cereals (pHC), which were used in a multicenter, open-label, OIT pilot study, in immunoglobulin E-mediated wheat allergy children (NCT01332084). The primary objective of the study was to test whether wheat allergic patients tolerate pHC and primary end point was the presence or not of immediate adverse reactions to pHC during the 1-day initial escalation phase (stepwise increased doses of pHC), with evaluation of the maximum dose tolerated. Of the 9 patients enrolled in the trial, 4 discontinued OIT because of mild to severe reactions at the initial escalation phase. The 5 patients who passed the escalation phase consumed pHC daily for 1 to 6 months. One of these patients withdrew due to noncompliance, whereas the 4 others completed the study and successfully passed the wheat challenge test at the end of the study. About 60% of the adverse events were unrelated to the study product. Our study provides preliminary evidence that pHC is tolerated by a subset of wheat allergic patients. Further studies are warranted to test its efficacy as a potential therapeutic option for wheat allergic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|